Clinical Dialogue: Strategies and Interventions in the Clinical Management of Patients with Dyslipidemia
This activity outlines the diagnosis and management of patients with dyslipidemia. Also available eCase Challenge and Monograph: Strategies and Interventions in the Clinical Management of Patients with Dyslipidemia. The eCase Challenge is approved for AAPA Category 1 Self-Assessment CME credit.
Member Fee: $0  Nonmember Fee: $0

Strategies and Interventions in the Clinical Management of Patients with Dyslipidemia

Lawrence Herman, MPA, PA-C, DFAAPA; John G. McGinnity, MS, PA-C, DFAAPA; Daniel Thibodeau, MHP, PA-C, DFAAPA

Cardiovascular disease (CVD) affects approximately one-third of the U.S. population. Much of CVD risk is attributed to hypercholesterolemia, or elevated LDL-C. For decades, statins have been the mainstay treatment to reduce LDL-C levels and their use is widely supported by clinical trial data that have shown significant reduction in CVD risk. Until recently, most nationally recognized guidelines have supported treating patients with lipid-lowering therapies to specific LDL-C goals based on the linkage with reduced CVD risk. However, the 2013 ACC/AHA guidelines have eliminated such specific treat-to-target approaches and recommend a two-tiered approach for the majority of patients. Such important changes to guidelines have created much confusion and concern among clinicians. Recent survey data indicated that approximately half of patients who are eligible for lipid-lowering therapy, based on current guidelines, are not receiving treatment, highlighting the current gap between treatment recommendations and implementation in clinical practice.

Though statins control LDL-C levels in the majority of patients, for some it is not enough to maintain adequate lipid control. The development and recent approval of PCSK9 inhibitors partially fulfills the previous unmet clinical need for alternative lipid-lowering therapies. An understanding of the clinical benefits and limitations of newly approved therapies will enhance the ability of PAs to provide therapeutic regimens that are suited to each patient. PAs should also be especially cognizant of medication nonadherence, which can likely be improved with simple changes at the patient, clinician and health system levels.

Educational Objectives

At the conclusion of this activity, the PA should be better able to:

  • Describe treatment recommendations for patients with elevated LDL-C.
  • Identify high-risk patients and determine the most appropriate treatment regimen.
  • Discuss statin therapy limitations, including lack of adequate response in certain populations.
  • Summarize the clinical efficacy and safety data on recently approved PCSK9 inhibitors and those in clinical development.
  • Outline barriers to treatment adherence and strategies to improve medication adherence through both the patient and clinical care team.

Accreditation Statement

This activity has been reviewed and is approved for a maximum of 0.50 AAPA Category 1 CME credit by the AAPA Review Panel. Participants should only claim credit commensurate with their participation in the CME activity. This program was planned in accordance with AAPA’s CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Approval is valid until November 30, 2017.

Responsibility Statement

AAPA takes responsibility for the content, quality, and scientific integrity of this CME activity.

Disclosure Policy Statement

It is the policy of AAPA to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the commercial interest of any commercial product discussed in an educational presentation. The participating faculty reported the following:

Faculty

Lawrence Herman, MPA, PA-C, DFAAPA
Moderator
Dean and Professor
College of Health Sciences
PA Studies
Gardner-Webb University
Boiling Springs, North Carolina
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

John G. McGinnity, MS, PA-C, DFAAPA
Program Director, PA Studies
Clinical Professor
Wayne State University
Eugene Applebaum College of Pharmacy and Health Sciences
Detroit, Michigan
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Daniel Thibodeau, MHP, PA-C, DFAAPA
Associate Professor
Director Clinical Education Recruitment and Support
Eastern Virginia Medical School
Norfolk, Virginia
No relationship with any commercial interests whose products or services may be mentioned during this presentation.

Activity Planners

Michael Speidel and Joanne Jeffers, Medical Logix, LLC and Judy Crespi-Lofton, MS, have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

AAPA Staff Activity Planners

Daniel Pace and Jennifer Williams have no relationship with any commercial interests whose products or services may be mentioned during this presentation.

Off-Label/Unapproved Product(s) Discussion

There are no references to off-label/unapproved uses of products in this program.

Disclaimer

The opinions and comments expressed by faculty and other experts, whose input is included in this program, are their own. This enduring material is produced for educational purposes only. Please review complete prescribing information of specific drugs mentioned in this program including indications, contraindications, warnings, and adverse effects and dosage before administering to patients.

Acknowledgement of Commercial Support

Supported by educational funding provided by Amgen.

AAPA offers no returns or refunds for online CME activities purchased through the AAPA store. All sales are final.


Type:     Internet Activity (Enduring Material)
361 Registered Users